ASH 2026 Program

A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation

How donor stem cell transplants became safer and more widely available, through better graft-versus-host disease prevention, new treatments, and more donor options.

• Roswell Park Comprehensive Cancer CenterMD moderating

• Talk
  Targeting Acute and Chronic GVHD with Effective New Therapies

  Recently approved treatments for steroid-resistant acute and chronic graft-versus-host disease, including ruxolitinib, belumosudil, axatilimab and stromal cells.

  • Dana-Farber Cancer InstituteMD presenting
• Talk
  New Standards in GVHD Prophylaxis: Towards a Future Without GVHD

  Newer ways to prevent graft-versus-host disease after donor transplants, such as engineered cell grafts, abatacept, and post-transplant cyclophosphamide.

  • Stanford UniversityMD, MS presenting
• Talk
  Donor for All: Increasing Access and Improving Outcomes

  Expanding donor options with mismatched unrelated, half-matched family, and umbilical cord blood transplants, and evidence that outcomes hold up across donor types.

  • Roswell Park Comprehensive Cancer CenterMD presenting

A New Treatment Paradigm for Follicular Lymphoma

Using molecular testing and circulating tumor DNA to gauge follicular lymphoma risk, and choosing among bispecific antibodies, CAR-T cells and other newer drugs.

• Novant Health Cancer InstituteMD moderating

• Talk
  Follicular Lymphoma: Role of Molecular Disease Characterization in Diagnosis and Prognosis

  • Rutgers Cancer InstituteMD, MSCE presenting
• Talk
  Novel Therapies for Follicular Lymphoma: Immune-Effector Cell Based

  • Novant Health Cancer InstituteMD presenting
• Talk
  Beyond Immune Effector Cell Therapy: Non-T-Cell Engaging Strategies in Follicular Lymphoma

  • University of Colorado Cancer CenterMD presenting

Addressing Resistance and Progression in Myeloproliferative Diseases

Why myeloproliferative neoplasms persist and progress despite therapy, from clone growth and inflammation to drug resistance, and new mutation-targeted treatments.

• Guy's and St Thomas' NHS Foundation Trust1 chair moderating

• Talk
  Mutation-Targeted Therapies in MPN: A New Dawn?

  Antibodies, vaccines and cell therapies aimed at mutant calreticulin, plus newer Janus kinase inhibitors, for myeloproliferative neoplasms.

  • Guy's and St Thomas' NHS Foundation Trust1 speaker presenting
• Talk
  Preventing Progression and Overcoming Resistance in MPNs

  Moving myeloproliferative neoplasm care toward earlier disease-modifying therapy and molecular monitoring, and handling resistance to Janus kinase inhibitors.

  • IRCCS Azienda Ospedaliero-Universitaria di BolognaMD, PhD presenting
• Talk
  Mechanisms of Clonal Persistence and Progression in MPN

  • Hannover Medical SchoolMD presenting

Advances in Management of Vascular Anomalies

Care for people with vascular malformations, from their lived experience to gene-guided treatment with repurposed cancer drugs that block growth signaling.

• University of Cincinnati College of MedicineMD moderating

• Talk
  Vascular Anomalies: Understanding the Healthcare Experiences of Patients and Caregivers

  What living with a rare vascular anomaly involves, from long diagnostic journeys and stigma to scarce experts, and how clinicians can help.

  • Washington University in St. LouisMD presenting
• Talk
  Targeted Therapies for Vascular Anomalies with RAS/MAPK Pathway Pathogenic Variants

  Treating fast-flow arteriovenous and complex lymphatic malformations driven by growth-signaling gene variants with repurposed cancer drugs such as trametinib.

  • Cincinnati Children's Hospital Medical CenterMD presenting
• Talk
  Targeted Therapies for PI3k/AKT/mTOR Pathway Disorders

  Using cancer drugs such as alpelisib that block the phosphoinositide 3-kinase growth pathway to treat slow-flow vascular malformations and overgrowth syndromes.

  • Hôpital Necker-Enfants MaladesMD, PhD presenting

Advancing Personalized Care in Classic Hodgkin Lymphoma

Tailoring classic Hodgkin lymphoma treatment to risk, response and circulating tumor DNA to cure with less toxicity, plus personalized follow-up care.

• Memorial Sloan Kettering Cancer CenterMD moderating

• Talk
  Therapeutic Approaches for Relapsed/Refractory Hodgkin Lymphoma in a Rapidly Evolving Treatment Landscape

  • Memorial Sloan Kettering Cancer CenterMD presenting
• Talk
  Personalized Care of Patients Cured from Hodgkin Lymphoma

  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of AtlantaMD, MSc presenting
• Talk
  Who Needs More, Who Needs Less? Risk-Adapted Frontline Care in Classic Hodgkin Lymphoma

  • NYU Langone HealthMD presenting

Are We There Yet? Improving Outcomes in MDS

Assessing and treating myelodysplastic syndromes, marrow failure cancers of older adults that can turn into acute myeloid leukemia, using newer risk systems.

• Moffitt Cancer CenterMD moderating

• Talk
  Straight to the Point: Targeted Therapies in MDS and CCUS

  Which patients with myelodysplastic syndromes or clonal cytopenia of undetermined significance are most likely to benefit from targeted drugs.

  • Yale Cancer CenterMD presenting
• Talk
  High Risk MDS: Is Two Better than One?

  Whether adding venetoclax to standard hypomethylating drugs helps patients with higher-risk myelodysplastic syndromes, based on a recent phase 3 trial.

  • Sylvester Comprehensive Cancer CenterMD, MS presenting
• Talk
  Choosing and Sequencing Anemia-Directed Treatment Options in Lower-Risk Myelodysplastic Syndromes

  Choosing and ordering newly approved and older anemia treatments for lower-risk myelodysplastic syndromes to get the best patient outcomes.

  • UT Southwestern Medical CenterMD presenting

Battle-Scarred Blood Cells: Hematologic Malignancies in Military Service Members

How military service and toxic exposures shape blood cancers in US veterans, including B-cell cancers and clonal hematopoiesis, and remote clinical trials for them.

• Uniformed Services University of the Health SciencesMD moderating

• Talk
  Beyond the Uniform: Understanding B-cell Malignancy Risks in Military Personnel

  • Veterans Health AdministrationMD, MS presenting
• Talk
  From Service to Cells: Toxic Exposures, Myeloid Malignancies, and Search for Pragmatic Solutions for Veterans

  • Veterans Health AdministrationMD presenting
• Talk
  Mission-Critical Care: Approaching a Service Member or Veteran with a Hematologic Malignancy

  • Uniformed Services University of the Health SciencesMD presenting

Building Hematology Capacity Globally

How education, training exchanges, mentorship and research networks can grow the hematology workforce and improve blood disease care in low-resource regions.

• University of Maryland, BaltimoreMD moderating

• Talk
  Showcasing ASH Resources for Continuing Medical Education for Local and International Trainees and Practitioners

  Digital learning, clinical guidelines, and visiting-trainee mentorship programs that expand hematology training worldwide and build lasting local expertise.

  • University of Alabama at BirminghamPhD, MBBS, MPH presenting
• Talk
  Highlights of ASH's Programs to Build Hematology Capacity Around the Globe in Education Research and Clinical Practice

  Career development, mentorship, research and leadership programs that support hematologists at every career stage and strengthen their home institutions.

  • Agrippa Ionescu Emergency Clinical HospitalMD presenting
• Talk
  The Impact of Hematology Global Partnerships

  How international consortia on acute leukemia and newborn screening in Africa standardize care and build diagnostic capacity in resource-limited settings.

  • University of São PauloPhD presenting

Chronic Lymphocytic Leukemia - From Clonal Evolution to Novel Therapies

Chronic lymphocytic leukemia in the targeted-drug era, covering clonal evolution, choosing and sequencing therapies, and transformation into aggressive lymphoma.

• UC IrvineMD moderating

• Talk
  A Clinical Perspective on Clonal Evolution in Chronic Lymphocytic Leukemia

  • Memorial Sloan Kettering Cancer CenterMD presenting
• Talk
  Treatment of Relapsed or Refractory CLL and of Richter Transformation

  • UC IrvineMD presenting
• Talk
  First and Second-Line Therapy of Chronic Lymphocytic Leukemia

  • University of CologneMD presenting

Classical Hematology: Innovation and Technology to Match Supply and Demand

Why demand for doctors treating non-cancer blood disorders outpaces supply, and how virtual care and AI language models can widen access.

• Yale UniversityMD moderating

• Talk
  Dealing with Workforce Challenges in Classical Hematology

  What drives the shortage of specialists in non-cancer blood disorders, and early results from efforts to close the gap.

  • Dana-Farber Cancer InstituteMD presenting
• Talk
  The Use of Virtual Care in Classical Hematology to Overcome Geographic and Resource Limitations

  How e-consults, video visits, and phone visits can widen access to non-cancer hematology care, plus the pitfalls and barriers of telehealth.

  • Yale UniversityMD presenting
• Talk
  Harnessing Artificial Intelligence for Hematology Learning and Practice

  Large language models in hematology practice, from decision support and patient education to paperwork, and simple ways to get better answers.

  • Innovative HematologyMD, MS presenting

Diffuse Large B-cell Lymphoma

The fast-changing treatment of diffuse large B-cell lymphoma, from new first-line combinations to CAR-T cells, bispecific antibodies and other targeted drugs.

• BC CancerMD moderating

• Talk
  Bispecific Antibodies and Cellular Therapies for Diffuse Large B-Cell Lymphoma

  CAR-T cells and bispecific antibodies for diffuse large B-cell lymphoma, covering efficacy, side effects, patient selection, sequencing, and drugs in development.

  • Memorial Sloan Kettering Cancer CenterMD, PhD presenting
• Talk
  Frontline Therapy of Diffuse Large B-Cell Lymphoma

  Recent trials of new first-line combinations for diffuse large B-cell lymphoma, and how subtype, stage, risk, age and heart health guide the choice.

  • BC CancerMD presenting
• Talk
  Novel Approaches for Diffuse Large B-Cell Lymphoma

  Where antibody-drug conjugates and other approved targeted drugs fit in diffuse large B-cell lymphoma care, and experimental combinations to overcome resistance.

  • National Cancer InstituteMD presenting

Don't Miss It! Methemoglobinemia: Inherited and Acquired

How to evaluate unexplained cyanosis, recognize inherited or acquired methemoglobinemia with lab tests, and manage it without costly unnecessary workups.

• Mayo ClinicMD moderating

• Talk
  Laboratory Testing in Methemoglobinemia

  Lab diagnosis of methemoglobinemia and sulfhemoglobinemia, where altered hemoglobin carries oxygen poorly, and test pitfalls in inherited versus acquired cases.

  • Mayo ClinicMD presenting
• Talk
  Acquired Methemoglobinemia: Who, Why, and What to Do

  Exposures that cause acquired methemoglobinemia, such as dapsone, rasburicase, topical anesthetics and recreational nitrites, and how to diagnose and treat it.

  • Oxford University HospitalsMD presenting
• Talk
  Inherited Methemoglobinemia: Not Only and Not Always Cyanosis. Different Pathophysiology, Different Mutated Genes, and Different Management

  The genetic causes of inherited methemoglobinemia, rooted in faulty methemoglobin reduction, with their varied symptoms, diagnosis and management.

  • Huntsman Cancer InstituteMD presenting

Driving CARs Safely- Preventing and Managing Intermediate and Long-Term CAR-T Toxicity

Later side effects of CAR-T therapy, including low blood counts, infections and immune problems, and how to monitor, prevent and treat them.

• Yale Cancer CenterMD moderating

• Talk
  Immune Determinants of Infections after CAR T- Cell Therapy: A Framework for Prevention and Management

  Infection risk after CAR-T cell therapy, traced from early immune damage to lasting antibody deficits, and how to prevent infections at each stage.

  • Memorial Sloan Kettering Cancer CenterMBBS presenting
• Talk
  Beyond Remission: Long-Term Hematopoietic Toxicity and Second Malignancies After CAR-T Cell Therapy

  Persistently low blood counts and second cancers after CAR-T therapy, including their frequency, causes, and how to monitor, prevent, and manage them.

  • University of PennsylvaniaMD presenting
• Talk
  A Practical Review of delayed Neurologic and Gastrointestinal Immune Toxicities After CAR-T Therapy in Multiple Myeloma

  Delayed nerve and gut side effects of CAR-T therapy for multiple myeloma, such as parkinsonism and colitis, and spotting and treating them early.

  • Yale Cancer CenterMD presenting

From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis

How clonal hematopoiesis, the age-related spread of mutated blood cells, fuels inflammation and artery and vein clots, and whether anti-inflammatory drugs help.

• Stanford University1 chair moderating

• Talk
  Clonal Hematopoiesis of Indeterminate Potential and Arterial Thrombosis: Mechanisms and Clinical Implications

  How clonal hematopoiesis alters myeloid cells to promote atherosclerosis, and how to evaluate affected patients for heart attack and stroke risk.

  • Stanford University1 speaker presenting
• Talk
  Role of Inflammasome Inhibitors in the Intersection of CH and Thrombosis

  Drugs that block the inflammasome and interleukin-1 signaling as a way to prevent clots and heart disease in people with clonal hematopoiesis.

  • Cleveland ClinicMD, MPH presenting
• Talk
  Clones and Clots: Clonal Hematopoiesis in the Management of Venous Thromboembolism

  Whether clonal hematopoiesis predicts blood clots in veins, their recurrence and bleeding on blood thinners, and what that means for anticoagulation decisions.

  • Ottawa Hospital Research InstituteMD, MSc presenting

Hemolysis Beyond Globin: Managing Inherited RBC Membrane and Enzyme Disorders

Genetic diagnosis of inherited red cell membrane and enzyme disorders, and treatment with pyruvate kinase activators, stem cell transplant or gene therapy.

• Massachusetts General HospitalMD moderating

• Talk
  Hematopoietic Stem Cell Transplantation in Severe Congenital Hemolytic Anemias

  Using stem cell transplants from matched or mismatched donors, now safer, to cure severe inherited hemolytic anemias, even in very young children.

  • Washington University in St. LouisMD presenting
• Talk
  Emerging Therapies for Treatment of Hereditary Hemolytic Anemias

  New treatments beyond transfusion and spleen removal for inherited hemolytic anemias outside hemoglobin disorders, from pyruvate kinase activators to gene repair.

  • Massachusetts General HospitalMD presenting
• Talk
  Management Considerations in Inherited Hemolytic Anemias

  How genetic testing is replacing stepwise diagnosis of inherited hemolytic anemias, with pyruvate kinase deficiency and mitapivat as a model of targeted therapy.

  • University of MichiganMD presenting

Improving Care of Patients with Sickle Cell Disease via Complement, Pain Control, and Trial Design

Sickle cell disease pain, from new insights into its biology to managing it at the level of health systems, strategies, and individual treatments.

• Emory UniversityMD moderating

• Talk
  Complement Inhibition in Sickle Cell Disease

  How the complement immune system drives hemolysis, vessel injury, pain crises and organ damage in sickle cell disease, and trials of complement-blocking drugs.

  • Emory UniversityMD presenting
• Talk
  After the Fall: Trial Design, National and International, in the Modern Era of Sickle Cell Disease

  Why sickle cell disease trials have struggled, and how more objective endpoints could let more patients enroll and speed new therapies.

  • University of Alabama at BirminghamMD presenting
• Talk
  What's New in Pain Management in Sickle Cell Disease?

  • Johns Hopkins UniversityMD presenting

Innovations in the Treatment of Pediatric AML

How gene-fusion biology in childhood acute myeloid leukemia is shaping targeted and antibody-drug conjugate treatments beyond standard chemotherapy.

• St. Jude Children's Research HospitalMD moderating

• Talk
  Targeted Therapies: From Genomic Insights to Therapeutic Strategies

  Genomic insights behind three targeted drug classes for childhood acute myeloid leukemia: blockers of B-cell lymphoma 2, menin and fms-like tyrosine kinase 3.

  • Stanford UniversityMD presenting
• Talk
  CAR T-Cell Therapy in Pediatric AML: Current Limitations and Emerging Opportunities

  Barriers facing CAR-T therapy in childhood acute myeloid leukemia and how multi-target designs and tumor-environment combinations might overcome them.

  • St. Jude Children's Research HospitalMD presenting
• Talk
  Antibody-Drug Conjugates in Pediatric AML: Delivering Targeted Payloads

  • IRCCS Azienda Ospedaliero-Universitaria di BolognaMD, PhD presenting

Longer Lives, New Challenges: Managing Thalassemia in 2026

Challenges as people with thalassemia live longer, including pregnancy, cheaper and safer gene therapy, and aging with the non-transfusion-dependent form.

• University of TorontoMD, MSc moderating

• Talk
  An Enigma Wrapped in a Mystery: NTDT in Adults

  Cases on monitoring adults with non-transfusion-dependent beta-thalassemia for early complications and when to intervene, including starting transfusions.

  • IRCCS Istituto Giannina GasliniMD presenting
• Talk
  Pregnancy in Transfusion-Dependent and Non-Transfusion Dependent Thalassemia (TDT and NTDT)

  Pregnancy risks for women with thalassemia, whether or not they need regular transfusions, and team-based care from pre-conception counseling to after delivery.

  • University of TorontoMD, MSc presenting
• Talk
  Changing the Paradigm of ß-Thalassemia Treatment: An Affordable, Less Toxic Gene Therapy

  Lowering the cost and infertility risk of gene therapy for transfusion-dependent thalassemia, using a lentiviral vector with a new conditioning protocol.

  • Guangzhou First People's Hospital1 speaker presenting

Managing Iron Status Before and During Pregnancy: Protecting Mother and Fetus

How iron deficiency, often from heavy periods, harms women before and during pregnancy and affects fetal brain development, with diagnosis and treatment strategies.

• Beilinson Hospital, Rabin Medical Center1 chair moderating

• Talk
  Heavy Menstrual Bleeding, Iron Deficiency, and Iron Deficiency Anemia: A Hidden Epidemic in Plain Sight

  Heavy menstrual bleeding as the overlooked top cause of iron deficiency in girls and women, and how gynecology and hematology can work together.

  • UCLAMD presenting
• Talk
  Intravenous Iron Therapy to Prevent Perinatal Iron Deficiency

  Early screening and treatment of iron deficiency in pregnancy, and evidence on how well and how safely intravenous iron works.

  • Beilinson Hospital, Rabin Medical Center1 speaker presenting
• Talk
  The Role of Iron in the Developing Brain

  How iron deficiency during pregnancy, even without anemia, alters fetal brain development and may raise lifelong risks of autism and other brain disorders.

  • University of MinnesotaMD presenting

Multiple Myeloma: The Future is Now

Multiple myeloma care today, covering T-cell redirecting therapy at early relapse, options after CAR-T failure, and maintenance for high-risk patients.

• Karmanos Cancer InstituteMD moderating

• Talk
  Treatment Sequencing After CAR-T Failure in Multiple Myeloma

  Choosing the next treatment for multiple myeloma that relapses after CAR-T cell therapy, weighing key clinical factors and approved and emerging options.

  • Stanford UniversityMD presenting
• Talk
  Bispecific Antibodies OR CAR-T in Early Relapse for Multiple Myeloma

  Comparing CAR-T cells with off-the-shelf bispecific antibodies for early-relapse myeloma, weighing trial evidence, risks, and the best treatment order.

  • UCSFMD presenting
• Talk
  Maintenance Therapy for High-Risk Multiple Myeloma

  Post-transplant maintenance for high-risk multiple myeloma, where lenalidomide alone falls short, using optimized single drugs, new combinations and immunotherapy.

  • Tisch Cancer Institute at Mount SinaiMD presenting

Navigating the Treatment Landscape of CNS Lymphomas

Evidence-based treatment of primary and secondary central nervous system lymphoma, including care of older patients and new immunotherapies and targeted drugs.

• Sylvester Comprehensive Cancer CenterMD moderating

• Talk
  The Role of CAR T-Cell Therapy, Novel Targeted Agents, and Emerging Therapies in CNS Lymphomas

  • Dana-Farber Cancer InstituteMD presenting
• Talk
  Management of CNS Involvement By Systemic Large B-Cell Lymphoma

  Large B-cell lymphoma spreading to the central nervous system, and risk-adapted care combining immunochemotherapy, transplant and cell therapy.

  • Sylvester Comprehensive Cancer CenterMD presenting
• Talk
  Management of Primary Central Nervous System Lymphoma

  Diagnosis and treatment of lymphoma arising in the central nervous system, including transplant consolidation, older patients, HIV-related disease and relapse.

  • University College London HospitalsPhD, MD presenting

Neutropenia: Updates in Diagnosis, Treatment, and Supportive Care.

How to diagnose inherited and acquired neutropenia and treat it with growth factor drugs, stem cell transplant, new targeted therapies and supportive care.

• University Hospital of HeraklionMD, PhD moderating

• Talk
  Supportive Care for Patients with Chronic Neutropenia

  • Children's Hospital of PhiladelphiaMD, PhD presenting
• Talk
  Treatment of Neutropenia: Cytokines and Beyond

  • IRCCS Istituto Giannina GasliniMD presenting
• Talk
  Diagnosis of Congenital and Acquired Neutropenia

  • University Hospital of HeraklionMD, PhD presenting

Optimizing Patient Care: Practicing Bloodless Medicine

Caring for patients who cannot receive blood transfusions, by choice or for lack of compatible blood, in surgery and blood cancer treatment.

• Monash UniversityMBBS moderating

• Talk
  Blood Management and Transfusion Practice in Patients Who Need Alternatives to Blood

  Principles of patient blood management for people who decline transfusion or have rare blood groups or multiple complex antibodies.

  • Monash UniversityMBBS presenting
• Talk
  Update on Transfusion Free Surgery

  Medicine and surgery performed without blood transfusions, with an overview of methods and newly published data on patient outcomes.

  • Englewood HealthMD presenting
• Talk
  Managing Autologous Bone Marrow Transplantation, CAR-T Therapy and Leukemia without Blood

  Delivering stem cell transplants using a patient's own cells, CAR-T therapy, and leukemia care to patients who refuse blood transfusions for religious reasons.

  • Pennsylvania HospitalMD presenting

Persistent Challenges in Managing Chronic Myelogenous Leukemia

Hard decisions in chronic myeloid leukemia after 25 years of kinase inhibitors, including drug choice, stopping treatment, progression, and pregnancy planning.

• Sant'Eugenio HospitalMD, PhD moderating

• Talk
  Update on CML-CP Management: From Choice of First-Line Therapy to Treatment-Free Remission

  • Cleveland ClinicMD, FACP presenting
• Talk
  Treating CML During Pregnancy

  • Sant'Eugenio HospitalMD, PhD presenting
• Talk
  Management of Chronic Myeloid Leukemia in Blast Phase

  • Jena University HospitalMD presenting

Tailored Transfusion Strategies for Alloimmunized Patients

Transfusion for sickle cell disease patients with antibodies against donor blood, from pre-transplant planning to finding matched units and treating reactions.

• Boston Children's HospitalMD moderating

• Talk
  Procurement of Blood for Highly Alloimmunized Patients

  What determines how fast antigen-matched blood can be found for patients with many red cell antibodies, and alternatives when none is available.

  • Emory UniversityMD, MSc presenting
• Talk
  Pre-Transplant Transfusion Strategies in Alloimmunized Patients with Sickle Cell Disease

  Transfusion planning, including red cell exchange, for antibody-sensitized sickle cell patients before transplant or gene therapy, and hemolysis afterward.

  • Boston Children's HospitalMD presenting
• Talk
  Immune-Mediated Transfusion Reactions in Sickle Cell Disease: A Practical Approach

  Telling apart hyperhemolysis and delayed hemolytic transfusion reactions in sickle cell disease, and why it matters for prognosis, future transfusions and treatment.

  • Seattle Children's HospitalMD presenting

Targeted Therapies for AML: Bulls Eye!

Menin inhibitors and other targeted drugs for acute myeloid leukemia, their use with frontline therapy, resistance to them and next-generation agents.

• University of North Carolina at Chapel HillMD moderating

• Talk
  Future of Targeted Therapies in AML

  Where acute myeloid leukemia treatment is heading, from new chemotherapy backbones and targeted drug pairings to next-generation drugs that overcome resistance.

  • MD Anderson Cancer CenterMD presenting
• Talk
  Flt3 inhibitors in newly diagnosed and relapsed patients

  Evidence behind current Flt3 inhibitor use in newly diagnosed and relapsed acute myeloid leukemia, and where investigational approaches are heading.

  • University of PennsylvaniaMD presenting
• Talk
  Targeted Therapy Approaches with Menin Inhibitors: Light at the End of the Tunnel?

  Menin inhibitors in relapsed acute myeloid leukemia, how resistance develops, and pairing them with azacitidine, venetoclax, or chemotherapy up front.

  • University of North Carolina at Chapel HillMD presenting

The Big Clot Problem

Risk grading of pulmonary embolism, clot-dissolving and catheter treatments for large vein clots, and preventing long-term leg damage after deep vein thrombosis.

• VersitiMD, MS moderating

• Talk
  Update on the management of Extensive DVT

  Recent trials on managing extensive deep vein thrombosis, and which patients benefit from catheter-directed clot removal for acute or chronic clots.

  • Washington University in St. LouisMD presenting
• Talk
  Update on the Management of Intermediate Risk Pulmonary Embolism

  Classifying and treating intermediate-risk pulmonary embolism, including when early intervention is worth its risks, under updated multi-society guidelines.

  • Weill Cornell MedicineMD presenting
• Talk
  Post-Thrombotic Syndrome and the Long-Term Burden of Extensive DVT

  Post-thrombotic syndrome after large pelvic and thigh vein clots, covering its course, diagnosis, risk factors, prevention and treatments under investigation.

  • Maastricht University Medical CenterMD presenting

The Golden Era of ALL Management: Rapid Advances Across the Age Spectrum

How blinatumomab, CAR-T cells and other immunotherapies are reshaping acute lymphoblastic leukemia care and reducing chemotherapy across all ages.

• Seattle Children's HospitalMD moderating

• Talk
  Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Improving Outcomes Beyond the Use of Two Pediatric Regimens

  Raising cure rates for teens and young adults with acute lymphoblastic leukemia by adding immunotherapy to pediatric-style regimens and limiting lasting harm.

  • Memorial Sloan Kettering Cancer CenterMD presenting
• Talk
  Older Adults Take the Lead: Revolutionizing B-cell ALL Treatment with Chemo-Sparing Approaches

  Chemotherapy-light care of older adults with B-cell acute lymphoblastic leukemia, using fitness and residual disease to sequence immunotherapies and transplant.

  • Mayo ClinicMD presenting
• Talk
  Next Steps for Treatment of Pediatric ALL in the Era of Frontline Chemo-Immunotherapy

  Whether adding inotuzumab or CAR-T to frontline treatment of childhood B-cell acute lymphoblastic leukemia can safely reduce chemotherapy and its toxicity.

  • Seattle Children's HospitalMD presenting

The Heart and Brain in Older Patients with Sickle Cell Disease

Heart disease, stroke, and cognitive decline in adults aging with sickle cell disease, and how heart ultrasound and other tools guide prevention and care.

• University of North Carolina at Chapel HillMD, MSCR moderating

• Talk
  Stroke in the Older Adult with Sickle Cell Disease

  Treating stroke in older adults with sickle cell disease with transfusion first and clot-busting drugs when suitable, and gaps in preventing repeat strokes.

  • University of North Carolina at Chapel HillMD, MSCR presenting
• Talk
  Addressing Cognitive Changes in Patients with Sickle Cell Disease

  Recognizing and screening for often-subtle cognitive decline in adults with sickle cell disease, and interventions to protect independence and quality of life.

  • Centre hospitalier de l'Université de Montréal (CHUM)MD, MSc presenting
• Talk
  Preventing a Broken Heart: Approaches to Cardiovascular Health in Adults with Sickle Cell Disease

  • Henri Mondor HospitalMD presenting

The Unusual Bleed: Cracking the Code of Platelet and Rare Bleeding Disorders

Diagnosing and managing inherited platelet and fibrinogen disorders and rare clotting factor deficiencies, where care relies on expert consensus more than trials.

• University of Colorado Anschutz Medical CampusMD, MSc moderating

• Talk
  Diagnosis and Management of Rare Bleeding Disorders

  • University of Colorado Anschutz Medical CampusMD, MSc presenting
• Talk
  The Unusual Bleed: Cracking the Code of Platelet Disorders

  • Brigham and Women's HospitalMD, PhD presenting
• Talk
  Diagnosis and Management of Fibrinogen Disorders

  • Geneva University HospitalsPhD presenting

Balancing Bleeding and Clotting: Extended VTE Treatment for Whom and at What Dose?

Longer-term anticoagulation for cancer-associated blood clots after the first six months, using new randomized trials to guide who continues and at what dose.

• Cleveland ClinicMD moderating

• Talk
  Anticoagulant Dose Reduction (who, how, and when)?

  Trial evidence on which cancer patients with blood clots can safely take reduced-dose oral anticoagulants long term, balancing recurrence against major bleeding.

  • Assistance Publique – Hôpitaux de Paris (AP-HP)MD, PhD presenting
• Talk
  VTE: Who Should Continue Anticoagulants Long-Term?

  Deciding which patients with venous blood clots should stay on blood thinners long term, using risk tools that weigh recurrence against bleeding.

  • McGill UniversityMD, MSc presenting

Bispecific Antibodies vs CAR T in Lymphoid Malignancies

Case-based comparison of bispecific antibodies and CAR-T for relapsed multiple myeloma and lymphoma, focusing on patient selection and treatment order.

• OhioHealthMD, MPH moderating

• Talk
  In favor of Bispecific Antibody Therapy: Lymphoma Perspective

  • City of HopeMD presenting
• Talk
  In favor of Bispecific Antibody Therapy: Myeloma Perspective

  • Vanderbilt University Medical CenterMD, MS presenting

Current Perspectives on Evolving Classification of Myeloid and Lymphoid Neoplasms

Debates from a 2026 expert meeting shaping the next World Health Organization classification of myeloid and lymphoid blood cancers.

• Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMD, MHS moderating

• Talk
  Myeloid Updates

  • MD Anderson Cancer CenterMD presenting
• Talk
  Lymphoid Updates

  • Lausanne University HospitalMD, PhD presenting

Public Health & Hematology: Results and Lessons from the PEN-Plus Model of Care for Severe, Chronic Non-Communicable Diseases like Sickle Cell Disease in Resource-Poor Areas

Decentralized care for sickle cell disease, rheumatic heart disease, and type 1 diabetes at rural African hospitals, under a World Health Organization program.

• Muhimbili University of Health and Allied SciencesMD, PhD moderating

• Talk
  Integrating Newborn Screening for SCD by CONSA, St Jude's Global Hematology and Ministries of Health into PEN-Plus in LMICs and Rural Settings

  Adding newborn sickle cell disease screening to chronic disease care in low-resource and rural regions, drawing on a Mozambique case study.

  • St. Jude Children's Research HospitalMD, MS presenting
• Talk
  Introduction to the PEN-Plus SCD Model of Care and Outcomes From the First Years of Implementation

  Outcomes for 3,000 rural sickle cell patients in seven countries under a decentralized care model, and lessons from training non-specialist health workers.

  • Brigham and Women's HospitalMD presenting

Rebooting the Immune System with Cellular Therapies

• Fred Hutch Cancer CenterDO moderating

• Talk
  Cellular Therapies for Severe Autoimmune Disease: From Case Series to Multicenter Trials and Hematologic Applications

  • Fred Hutch Cancer CenterDO presenting

Splenectomy in Membrane Disorders and Enzymopathies: Who, When and How?

When removing the spleen helps people with inherited red cell membrane and enzyme disorders, and how to manage surgery and long-term risks.

• Nationwide Children's HospitalDO moderating

• Talk
  Indications and Timing of Splenectomy in Hereditary Hemolytic Anemia

  When and how to remove the spleen in inherited red cell membrane and enzyme disorders, weighing benefit against lifelong infection and clotting risks.

  • University of PennsylvaniaMD, PhD presenting
• Talk
  Techniques for Splenectomy and Partial Splenectomy and Peri-splenectomy Care

  Partial versus total spleen removal, pre-surgery vaccines and counseling, and preventing severe infection and clots after the operation.

  • Zucker School of Medicine at Hofstra/Northwell1 speaker presenting

ALL

• Seattle Children's HospitalMD presenting

Cold Agglutinin Disease and Related Complement-Mediated Hemolytic Anemia

• Boston Children's HospitalMD presenting

Follicular Lymphoma

• Novant Health Cancer InstituteMD presenting

Heavy Menstrual Bleeding in Women with Bleeding Disorders

• University of Colorado Anschutz Medical CampusMD, MSc presenting

HLH and Related Hyperinflammatory Syndromes

• Cincinnati Children's Hospital Medical CenterMD presenting

Large B-Cell lymphoma

• BC CancerMD presenting

MPN

• Hannover Medical SchoolMD presenting

Pediatric AML

• Stanford UniversityMD presenting

Refractory ITP Unresponsive to Steroids and Thrombopoietin Agonists

• Brigham and Women's HospitalMD, PhD presenting

TTP in the Caplacizumab Era

• University of PennsylvaniaMD, MS presenting

Announcement of Awards: J. Evan Sadler Award for Mentorship and Bernard Forget Award for Mentorship

• Stanford UniversityMD moderating
• Medical College of WisconsinMD presenting
• University of PittsburghMD presenting

Announcement of Awards: Roland B. Scott-Charles Drew Excellence in Equity Award and Wallace H. Coulter Award for Lifetime Achievement in Hematology

• Stanford UniversityMD moderating
• UCSF Benioff Children's HospitalsMD presenting
• Wake Forest University School of MedicineMD presenting

Announcement of Awards: William Dameshek Prize, Janet Rowley Basic Science Medal, and Helen M. Ranney Clinical and Translational Science Medal

• Dana-Farber Cancer InstituteMD, PhD presenting
• Stanford UniversityMD moderating
• Children's Hospital of PhiladelphiaMD presenting
• Walter and Eliza Hall Institute (WEHI)MBBS, PhD presenting

Best of ASH

• University of PennsylvaniaMD, PhD moderating
• University of Colorado Anschutz Medical CampusMD moderating

ASH-EHA Joint Symposium: Novel Approaches to Cell Engineering in Hematopoietic Cell Transplantation

• Stanford UniversityMD moderating
• Ulm UniversityMD moderating

• Talk
  Immune Regulatory Mechanisms to Improve Outcomes following HSCT

  • University of Colorado Anschutz Medical CampusMD, PhD presenting
• Talk
  Strategies to Improve Outcomes following Haploidentical Transplantation

  • University of Perugia1 speaker presenting

E. Donnall Thomas Lecture and Prize

• Stanford UniversityMD moderating

• Plenary
  Leveraging the Biology of the MLL (KMT2A) Complex to Discover New Therapies for Leukemia

  • Dana-Farber Cancer InstituteMD, PhD presenting

Ernest Beutler Lecture and Prize

• Stanford UniversityMD moderating

• Plenary
  Clinical/Translational Science Speaker

  • Albert Einstein College of MedicineMD, PhD presenting
• Plenary
  Basic Science Speaker

  • Walter and Eliza Hall Institute (WEHI)PhD presenting

Ham-Wasserman Lecture

• Stanford UniversityMD moderating

• Plenary
  CD7 CAR-T Therapy in T-cell Acute Leukemia/Lymphoma: Past, Present and Future

  • Beijing Lu Daopei HospitalMD presenting

Presidential Symposium

• Stanford UniversityMD moderating

• Plenary
  Role of EPO/EPOR in Tolerance Induction

  • Stanford UniversityMD, PhD presenting
• Plenary
  Role of the Adult Thymus in Health and Disease

  • Harvard Stem Cell InstituteMD presenting
• Plenary
  Novel Approaches to in vivo Therapy

  • UC BerkeleyPhD presenting

Beyond the Niche: Systemic Regulation of Hematopoietic Stem Cell Numbers in Health and Disease

• Albert Einstein College of MedicineMD, PhD presenting

Building Bone Marrow in a Dish: Bioengineered Niches for Understanding and Treating Platelet Disorders

• Tufts UniversityMD presenting

Chemoresistance in Acute Myeloid Leukemia

• Cancer Research Center of ToulousePhD presenting

Engineering Tolerance: CAR-Tregs and the New Era of Cell Therapy for Autoimmunity

• UCSFPhD presenting

From GATA2 to SAMD9: Discovering the Genetic Architecture of Pediatric Myelodysplastic Syndrome and Bone Marrow Failure

• St. Jude Children's Research HospitalMD, PhD presenting

From Ribosomes to Risk Stratification: Decoding Inherited Bone Marrow Failure and Its Path to Leukemia

• Boston Children's HospitalMD PhD presenting

From Splicing Mutations to Cancer Neoantigens: A Decade of Targeting RNA Biology in Leukemia

• Memorial Sloan Kettering Cancer CenterMD presenting

Reading the Epigenetic History of Lymphoma: From Cell of Origin to Mitotic Clocks and Clinical Outcome

• IDIBAPSMD presenting

Why the Mouse Matters: Building Faithful Models of Multiple Myeloma

• Mayo ClinicPhD presenting

αIIbβ3: One Receptor, Two Drugs, and the Long Road of Translational Platelet Biology

• Rockefeller UniversityMD presenting

Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward

Old and new tools, from biochemistry and mouse models to spatial gene mapping and AI, revealing weak points and treatment biomarkers in multiple myeloma.

• Dana-Farber Cancer InstituteMD moderating

• Talk
  Show Me Your Face and I Will Understand Your Purpose: How Protein Structure Informs Function

  Structural biology uncovered a second route for destroying the transcription factors multiple myeloma depends on, making that pathway a possible drug target.

  • Dana-Farber Cancer InstitutePhD presenting
• Talk
  Running on Wheels: How Mouse Models Inform the Study of Plasma Cell Biology

  Immune-competent mouse models of multiple myeloma that mimic its interplay with bone marrow, used to test new immune and cell therapies before trials.

  • Mayo ClinicPhD presenting
• Talk
  Getting by With a Little Help From Friends: Novel Approaches to Study Myeloma Microenvironment

  Combining single-cell RNA and receptor sequencing with protein analysis found a new killer T cell type in myeloma that predicts who benefits from immunotherapy.

  • German Cancer Research Center (DKFZ)MD, PhD presenting

Balancing the Blood: Immune Control of Stem Cell Fidelity

Immune signals shape blood stem cells from before birth onward, and immune cells police and remove damaged or pre-cancerous stem cells throughout life.

• Albert Einstein College of MedicinePhD moderating

• Talk
  Regulation of HSCs by the Adaptive Immune System

  How T cells and other adaptive immune cells recognize and clear mutant blood stem cells, and harnessing this to prevent premalignant clonal expansion.

  • St. Jude Children's Research HospitalMD, PhD presenting
• Talk
  The Impact of Perinatal Inflammation on HSC Fitness

  How fetal blood stem and progenitor cells respond to inflammation before birth, leaving lasting marks on the immune system after birth.

  • University of UtahPhD presenting
• Talk
  Regulation of HSCs by the Innate Immune System

  New technology for watching cells divide inside a living animal, revealing what drives healthy and cancerous blood production and how cell therapies behave.

  • Biogipuzkoa Health Research InstitutePhD presenting

Built to Clot, Built to Break: Structural Control of Hemostasis and Fibrinolysis

Protein shape, force-sensitive interactions, and clot architecture govern how blood clots form and dissolve, pointing to new ways to treat bleeding.

• Leiden University Medical CenterPhD moderating

• Talk
  Structural Insights into Mechanisms

  How an enzyme chemically modifies vitamin K dependent proteins, and how that step shapes blood clotting control, bone building, and blood vessel signaling.

  • Washington University in St. LouisPhD presenting
• Talk
  Novel Regulators of Hemostasis

  How the redox state of disulfide bonds in clotting proteins shapes their structure and autoantibody targeting in hemophilia A and antiphospholipid syndrome.

  • Centenary InstitutePhD presenting
• Talk
  Novel Regulators of Fibrinolysis

  How fibrin network structure, fiber packing, and mechanical tension decide how easily clots dissolve, and using clot mechanics as disease biomarkers.

  • Rutgers UniversityPhD presenting

Cutting-Edge Insights into Pro-Thrombotic Anti-Platelet Factor 4-Associated Disorders

Blood-clotting disorders driven by antibodies to platelet factor 4, including heparin- and vaccine-induced forms, compared on causes, diagnosis, and treatment.

• SanquinMD PhD MSc moderating

• Talk
  The Clone Wars: Monoclonal Gammopathy of Thrombotic Significance (MGTS)

  • Mayo ClinicMBBS, PhD presenting
• Talk
  Heparin-Induced Thrombocytopenia (HIT): How Heparin Sparks Thrombosis

  How the blood thinner heparin binds a platelet protein and provokes antibodies that drop platelet counts and paradoxically cause dangerous clots.

  • Children's Hospital of PhiladelphiaMD, PhD presenting
• Talk
  Pulling the Antibody Trigger in Vaccine-Induced Thrombotic Thrombocytopenia (VITT)

  A viral protein that resembles a platelet protein appears to trigger the clotting disorder seen after some adenovirus vaccines and natural adenovirus infection.

  • Flinders UniversityPhD presenting

How Clots Form and Fall Apart: From Engineered Vessels to Targeted Therapies

Lab-built vessels on chips and large-vessel models reproduce how clots form under real flow, plus imaging that finds clots and delivers drugs to them.

• University of SydneyMBBS, PhD moderating

• Talk
  Vessel on a Chips, Organoids and Clots: A New Era in Thrombosis Research

  Tiny engineered vessels that keep their lining alive for weeks, letting researchers watch a clot form, organize, and dissolve while testing new drugs.

  • Emory UniversityMD, PhD presenting
• Talk
  Beyond Platelets and Coagulation: Novel Anti-Thrombotic Targets

  An antibody binding only activated platelets lets doctors image a clot and deliver clot-busting drugs straight to it, produced in the body from mRNA.

  • Baker Heart and Diabetes InstitutePhD presenting
• Talk
  Sticky Surfaces: Mechanistic Insights Into Macrovascular Clot Formation

  How clots form in large arteries, fibrin's role in halting clot growth, and new artery-mimicking and mouse models for testing stent thrombosis.

  • InsermPhD presenting

Innovations in the Detection and Characterization of Chemoresistant Cells in AML: From Molecular MRD to Molecular Resistance Mechanisms

Detecting the few leukemia cells left after treatment in acute myeloid leukemia, which tests to use when, and how to kill the survivors.

• Texas Children's Cancer and Hematology CenterMD, PhD moderating

• Talk
  Emerging Technologies for Molecular MRD Detection

  Methods for finding leftover leukemia cells, from gene amplification tests to sequencing, plus new blood tests reading cancer nucleic acids in circulation.

  • Hannover Medical SchoolMD presenting
• Talk
  Biological Insights into Resistant Cells

  Leukemia cells that survive treatment and seed relapse lean on mitochondrial energy production, and their metabolic and surface features could be drug targets.

  • Cancer Research Center of ToulousePhD presenting
• Talk
  Current Clinical Applications for Molecular MRD in Myeloid Malignancies

  Guidelines for testing leftover leukemia cells by their genetic markers, and the multi-country studies proving that acting on those results changes outcomes.

  • Fralin Biomedical Research Institute Cancer Research Center1 speaker presenting

Iron Homeostasis Across the Lifespan in Health and Disease

Iron balance from fetal life to old age, what goes wrong in deficiency and overload, and the pathways being targeted to treat iron-related disorders.

• Children's Hospital of PhiladelphiaPhD moderating

• Talk
  Consequences of Maternal Abnormal Iron Delivery to the Fetus

  How maternal iron deficiency or overload, including in thalassemia, alters placental iron transfer and fetal development, even affecting sex determination.

  • UCLAPhD presenting
• Talk
  The Role of Iron in Disease Progression

  Iron overload in myelodysplastic syndromes, built up by failed red cell production and repeated transfusions, and how it pushes disease toward acute leukemia.

  • Emory UniversityPhD presenting
• Talk
  Iron and Novel Pathologies: Beyond Erythropoiesis

  Liver signaling that controls the iron hormone hepcidin, and new links between that pathway and fatty liver disease that could open treatment options.

  • San Raffaele Scientific InstitutePhD presenting

JOINT SESSION - Bridging the Gap: Research and Clinical Implications of Emerging Technologies in Hematology

AI, spatial multi-omics, epigenetics, and genetics are reshaping how blood cancers are diagnosed and classified in the pathology lab.

• Simon Fraser UniversityPhD moderating
• University Hospital TübingenMD moderating

• Talk
  New Dimensions in the Classification of Aggressive B-cell Lymphomas: What Are We Missing?

  Single-cell profiling, spatial gene mapping, and whole genome sequencing trace how aggressive B cell lymphomas develop from common precursor cells.

  • BC CancerMD presenting
• Talk
  Spatial Transcriptomics/Multiomics in Lymphoma and Leukemia

  Mapping gene activity in place across tumor tissue to reveal architecture and immune escape in lymphoma and leukemia, refining diagnosis and risk scoring.

  • Yale UniversityMD presenting
• Talk
  New Developments in AI for Flow Cytometry Diagnostics

  AI analysis of flow cytometry data to detect and classify blood cancers and predict their genetic abnormalities, as an early stand-in for genomic testing.

  • Hospital of the University of PennsylvaniaMD, PhD presenting
• Talk
  Epigenome in the Classification of Lymphomas

  DNA methylation patterns sharpen lymphoma classification and can reconstruct a cancer cell's history, offering prognostic markers and outcome prediction.

  • IDIBAPSMD presenting

JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy

Every stage of the RNA life cycle, from splicing to chemical marks, shapes blood stem cells and blood cancers, pointing to new treatments.

• University of PennsylvaniaMD, PhD moderating
• Oregon Health & Science UniversityPhD moderating

• Talk
  Novel Uses of RNA as Therapeutics

  Synthetic RNAs that exploit faulty splicing to kill cancer cells with splicing-factor mutations, and mRNA vaccines against mis-spliced protein fragments.

  • Memorial Sloan Kettering Cancer CenterMD presenting
• Talk
  New Frontiers in RNA Biology

  Small RNAs that carry sugar chains and sit on the cell surface, how chemistry finds them, and what they mean for immunity.

  • Boston Children's HospitalMD, PhD presenting
• Talk
  RNA Binding Proteins in Hematopoiesis and Leukemia

  Proteins that bind RNA control normal and leukemic blood formation, and mutations in untranslated parts of messages can rewire those programs in leukemia.

  • Princess Margaret Cancer CentrePhD presenting
• Talk
  Targeting RNA Modifications in the Clinic

  Chemical methyl marks on RNA help drive myeloid cancers, and the enzymes that add them are now drug targets tested in patients.

  • University of CambridgePhD presenting

Power Sharing: Transplantation and Cellular Therapy in Autoimmunity

Cell therapies built for blood cancers now treat autoimmune disease by wiping out B cells, raising questions of patient selection, biomarkers, and toxicity.

• Royal Melbourne Hospital1 chair moderating

• Talk
  Promoting the Peacekeepers: Treg Adoptive Therapies to Re-Establish Tolerance

  Regulatory T cells redirected with chimeric antigen receptors to restore immune tolerance in rheumatoid arthritis, from lab studies to clinical findings.

  • UCSFPhD presenting
• Talk
  Barrier to Feature: Immunosuppression-Resistant Off-the-Shelf CAR T Cells for Severe Autoimmune Disorders

  • Baylor College of MedicineMD presenting
• Talk
  Ex Vivo or in Vivo CAR-T for Autoimmunity

  Stripping out B cells with engineered T cells in rheumatology, the long-term effects on immunity, and whether such cells could be made inside patients.

  • University Hospital ErlangenMD presenting

Rethinking Antiplatelet Strategies: Selective Blockade, Broad-Acting Drugs, and Beyond

Safer clot prevention by selectively blocking the platelet signals that grow a clot, instead of shutting platelets down and raising bleeding risk.

• Washington University in St. LouisPhD moderating

• Talk
  Precision Antiplatelet Therapy: Targeting Platelet-Specific Pathways for Safer and Smarter Inhibition

  Zalunfiban, a platelet receptor blocker designed from crystal structures, given under the skin in the ambulance to curb clotting in heart attacks.

  • Rockefeller UniversityMD presenting
• Talk
  Striking the Balance: Selectivity vs Breadth in the Next Generation of Antiplatelet Drugs

  Molecules that tag platelet signaling proteins for destruction give long-lasting clot protection without impairing normal wound sealing.

  • University of BristolPhD presenting
• Talk
  The Power of Broad Inhibition: Why Pan-Platelet Blockade Remains the Gold Standard

  Blocking one protein interaction inside platelets stops dangerous clots while normal wound sealing continues, and also calms clot-driven inflammation.

  • University of Illinois ChicagoMD, PhD presenting

T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics

Memory T cells that stay put in tissues drive chronic inflammation after infection, in tumors, and after transplant, and the pathways keeping them alive.

• RegeneronMD moderating

• Talk
  Trm Phenotype and Functions

  How T cells come to reside permanently in tissues during infection and cancer, how to study them, and therapies that harness them.

  • MD Anderson Cancer CenterMD, PhD presenting
• Talk
  Coming to Trms with GVHD

  Tissue-resident memory T cells that sustain chronic graft-versus-host disease, the stem-like and progenitor subsets in target organs, and how they mature.

  • City of HopeMD, PhD presenting
• Talk
  Molecular Mechanisms of Trm Maintenance, Activation, and Proliferation

  Signaling proteins of the common gamma chain family work together to keep tissue-resident memory T cells self-renewing, suggesting cytokine-based treatments.

  • VersitiPhD presenting

The Great Escape- Immune Evasions in Bone Marrow Failure

Mutant blood cell clones in bone marrow failure, and how sequencing reveals whether they drive recovery, reversion, or progression to a myeloid cancer.

• King's College HospitalMD, MBBS, FRCPath moderating

• Talk
  Clonal Dominance in VEXAS

  An adult-onset inflammatory blood disorder caused by mutation of one protein-tagging enzyme, and how extra mutations shape inflammation and treatment.

  • Mayo ClinicMD, MBBS presenting
• Talk
  Escape Clones in Immune Mediated BMF

  How blood stem cells in aplastic anemia dodge attacking T cells by disabling a tissue-type gene, repeatedly and independently, years before diagnosis.

  • St. Jude Children's Research HospitalMD, PhD presenting
• Talk
  Clonal Selection of Somatic Mutations in Immune Mediated BMF

  How acquired mutations are selected in immune and inherited bone marrow failure, and how genomic tests can track clones that progress to myeloid cancer.

  • National Heart, Lung, and Blood InstitutePhD presenting

Through Space and Time: Spatiotemporal Organization of Haematopoiesis in Health and Disease

Blood stem cells do not share one uniform niche, and location, chromosome dosage, and body-wide feedback shape them in development, disease, and aging.

• University College LondonMD moderating

• Talk
  Numbers and Fates: Decoding HSC Abundance and Decisions

  What sets the number of blood stem cells in the body, and how they read local and body-wide signals to rest, self-renew, or specialize.

  • Albert Einstein College of MedicineMD, PhD presenting
• Talk
  Resilience and Dynamic Expansion and Resilience of Adult Calvarial Bone Marrow

  How the blood vessels of bone marrow vary between skeletal sites such as the skull, and how they remodel with aging and injury.

  • Max Planck Institute for Molecular BiomedicineDPhil presenting
• Talk
  Time, Place, and Destiny: Fetal Liver Niches Steering HSC Fate

  How extra chromosomes, as in trisomy 18 and 21, rewire gene regulation and chromatin in fetal blood formation, studied with single-cell multiomics.

  • University of CopenhagenPhD presenting

Understanding and Targeting Metabolism in Erythrocyte Development and Disorders

Metabolism drives red blood cell production, and targeting sugar, nucleotide, amino acid, and mitochondrial pathways could fix faulty production in thalassemia.

• Monash UniversityMBBS, PhD moderating

• Talk
  Metabolic Switches Underpin Erythropoiesis

  A link between glutamine handling and heme production in maturing red cells, and how losing that detoxifying step goes wrong in beta-thalassemia.

  • St. Jude Children's Research HospitalPhD presenting
• Talk
  The Interplay Between Pyrimidine Synthesis and Ferroptosis in Erythropoiesis

  How nucleotide building interacts with an iron-driven cell death from damaged membrane fats, a major cause of failed red cell production in beta-thalassemia.

  • University of Rochester Medical CenterMD, PhD presenting
• Talk
  Developing Metabolism-Targeted Therapies in Red Cell Disorders

  Why red blood cells depend on the glycolysis enzyme pyruvate kinase, and trial results for mitapivat, a drug that boosts it, in anemias.

  • University of VeronaMD presenting

Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes

Genomic tools and better disease models are changing how inherited blood disorders in children are found, understood, and managed.

• Children's Hospital of PhiladelphiaMD moderating

• Talk
  Neutropenia Uncovered: The Role of Genetic Testing

  Genetic testing for low neutrophil counts, covering which patients to test, how to read inherited and acquired variants, and what results mean for care.

  • Boston Children's HospitalMD PhD presenting
• Talk
  New Insights into Inherited Thrombocytopenias

  A lab-built three-dimensional bone marrow model for studying inherited low platelet counts and testing treatments tailored to each patient.

  • Tufts UniversityMD presenting
• Talk
  Decoding the Mysteries of the VWF Gene

  Long-read sequencing to resolve complex variation in the gene for a major blood-clotting protein, and its promise as a first-line diagnostic test.

  • University of WashingtonMD, PhD presenting

CAR-T Manufacturing Across Nations: From Low-to-Middle-Income Academic Platforms to Frontier Innovations in Global Access

• Talk
  From Frontier to Field: Manufacturing Innovations That Could Lower Barriers to CAR-T Access in LMICs

  Manufacturing advances from wealthy countries that could make CAR-T therapy cheaper and easier to deliver in low- and middle-income countries.

  • Dana-Farber Cancer InstituteMD, PhD presenting
• Talk
  Centralized and Decentralized Models of CAR-T Manufacturing: Insights from a Latin American Academic Platform on the Science of Global Access

  How academic centers in Latin America and the Middle East weigh central versus on-site CAR-T manufacturing to widen access in lower-resource countries.

  • Hospital Sírio-LibanêsMD presenting

Decoding Macrophage Diversity in Lymphomas: Spatial Insights and Immunotherapeutic Implications

• Talk
  Macrophage–HRS Cell Crosstalk Driving Immune Evasion and Therapy Resistance in Hodgkin Lymphoma

  Single-cell and spatial studies of how macrophages help the rare malignant cells of classic Hodgkin lymphoma survive, evade immunity and resist treatment.

  • Princess Margaret Cancer CentreMD, PhD presenting
• Talk
  Dark Zone Macrophages as Mediators of T-Cell Exhaustion and Immunotherapy Response in Lymphoma

  How macrophage types in the germinal center dark zone of diffuse large B-cell lymphoma relate to T-cell exhaustion, patient outcome and immunotherapy response.

  • Cancer Science Institute of SingaporeMBBS, MRCP, PhD presenting

Greasy Situations: Unraveling Lipid-Mediated Therapy Resistance

• Talk
  Lipids and Therapy Resistance in Multiple Myeloma

  How fatty acids shift myeloma cells' reliance on a cell-survival protein and change their sensitivity to the drug venetoclax.

  • Winship Cancer Institute of Emory UniversityPhD presenting
• Talk
  Lipids Biomarkers of Therapy Relapse in Acute Myeloid Leukemia

  Using a patient's blood lipid profile to predict treatment response and relapse in acute myeloid leukemia, and targeting lipids to overcome drug resistance.

  • Cincinnati Children's Hospital Medical CenterPhD presenting

Illuminating the Dark Corners in the Genomes of Lymphoid Neoplasms

• Talk
  Dissecting the Functional Consequence of Non-Coding Variants

  How CRISPR screens and single-cell methods show the way non-coding DNA variants alter gene regulation in acute lymphoblastic leukemia.

  • St. Jude Children's Research HospitalPhD presenting
• Talk
  Clinical Relevance of Non-Coding Mutations

  Why non-coding mutations, often left by the machinery that diversifies antibodies, matter for the biology, subtypes and clinical behavior of B-cell lymphomas.

  • BC CancerPhD presenting

Sticky Situations: Glycans in Classical and Malignant Hematopoiesis

• Talk
  Novel Insights Into the Glycobiology of Hemostasis and Thrombosis

  How sugar chains on platelet surface proteins form the targets of antiplatelet antibodies, and what that means for clotting and bleeding disorders.

  • Brigham and Women's HospitalMD, PhD presenting
• Talk
  Glycans in the Pathogenesis and as a Therapeutic Target in Myeloid Malignancies

  How sugar chains on growth factor receptors shape their function, drive chemotherapy resistance and immune evasion, and could be drug targets in myeloid cancers.

  • RadboudumcPhD presenting

AI Models of Cell State for the Design of Next-Generation T Cell Therapies

Using AI trained on patient data to predict which T cell states make CAR-T therapy work, moving cell design beyond trial and error.

• Stanford UniversityPhD moderating

• Talk
  Clinically Informed AI Models for Predicting and Engineering CAR T Cell Function

  Predicting which lymphoma patients respond to CAR-T from single-cell RNA profiles of the infused cells, then simulating better designs on a computer.

  • Stanford UniversityPhD presenting
• Talk
  State-of-the-Art Single-Cell Foundation Models for Future Cell Design

  AI foundation models and agents that simulate cells across scales to design cell states for precision therapies and predict patient drug responses.

  • Arc InstitutePhD presenting
• Talk
  Scalable Frameworks for Multimodal Data Analysis and Next-Generation Cell Models

  Computational tools that merge multimodal single-cell data and large perturbation screens into predictive models linking genes, cell state, and phenotype.

  • New York Genome CenterPhD presenting

Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies

How to design clinical trials that alter the gut microbiome in blood cancers, including fecal microbiota transplants to prevent graft-versus-host disease.

• Memorial Sloan Kettering Cancer CenterMD, MS, DipABLM moderating

• Talk
  Dietary and Prebiotic Intervention Strategies

  Changing gut bacteria through diet and prebiotic fiber, the evidence linking food to patient outcomes, and how to design rigorous nutrition trials.

  • Memorial Sloan Kettering Cancer CenterMD, MS, DipABLM presenting
• Talk
  Live Bacterial Therapeutic Intervention Strategies

  Giving patients defined mixtures of live bacteria to reshape the gut and cut infections after a donor stem cell transplant.

  • Memorial Sloan Kettering Cancer CenterMD presenting
• Talk
  Fecal Microbiota Transplant Intervention Strategies

  • Hôpital Saint-AntoineMD, PhD presenting

In Vivo Gene Modification Approaches for Classical and Malignant Hematologic Disorders

Editing blood stem cells and making CAR-T cells inside the body, using viral and non-viral delivery to avoid costly manufacturing and harsh conditioning.

• Imagine InstitutePhD moderating

• Talk
  Lipid Nanoparticle (LNP) Delivery to Hematopoietic Stem Cells in Vivo

  Delivering mRNA and gene editors to blood stem cells inside the body with lipid nanoparticles, including editing before birth for inherited blood diseases.

  • Children's Hospital of PhiladelphiaMD presenting
• Talk
  Viral Vector-Mediated In Vivo Hematopoietic Stem Cell Gene Therapy: Targets, Delivery, and Selection

  Delivering gene therapy to blood stem cells with viral vectors, plus surface marker edits that let corrected cells be enriched inside the body.

  • Fred Hutch Cancer CenterPhD presenting
• Talk
  In Vivo Car T Cell Generation to Treat Cancer and Autoimmune Disorders

  Reprogramming a patient's T cells inside the body into CAR-T cells using retargeted lentiviral vectors, for cancer and autoimmune disease.

  • Massachusetts Institute of TechnologyPhD presenting

Lab-Grown Red Blood Cells: From Scalable Manufacturing to Clinical Translation

Growing red blood cells in the lab for transfusion, and the hurdles left in progenitor supply, differentiation, high-density culture, and first human studies.

• Albert Einstein College of MedicinePhD moderating

• Talk
  Unmet Needs in Transfusion Medicine: Alloimmunization, Rare Blood Types, and the Case for Lab-Grown Red Cells

  Patients with rare blood types or antibodies against donor red cells struggle to find matches, and engineered lab-grown cells could supply tailored units.

  • Children's Hospital of PhiladelphiaMD presenting
• Talk
  Scalable Manufacturing of Lab-Grown Red Blood Cells: Overcoming Metabolic and Bioprocess Constraints

  Engineering self-renewing red cell precursors that grow without added growth factors, and high-density bioreactors, to mass-produce lab-grown red blood cells.

  • Albert Einstein College of MedicinePhD presenting
• Talk
  Clinical Translation of Lab-Grown Red Blood Cells: First-in-Human Studies and Early Outcomes

  Early human trials of lab-grown red blood cells, covering their safety, survival in circulation, manufacturing consistency, and regulatory path to transfusion.

  • Scottish National Blood Transfusion ServicePhD presenting

Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS

Single-cell and spatial maps of bone marrow in acute myeloid leukemia and myelodysplastic neoplasms, showing how immune cell niches help tumors evade immunity.

• Dana-Farber Cancer InstituteMD moderating

• Talk
  Spatial Niches within the AML/MDS Bone Marrow Immune Microenvironment

  • Memorial Sloan Kettering Cancer CenterMD presenting
• Talk
  Phenotypes and Specificities of AML/MDS-Associated T Cell Populations

  What T cells in leukemic and pre-leukemic bone marrow look like, where they sit, and which are worn out, guiding biomarkers and new immunotherapies.

  • MD Anderson Cancer CenterMD, PhD presenting
• Talk
  AML Immune Escape Mechanisms Driving Post-Therapy Relapse

  Why acute myeloid leukemia returns after chemotherapy, donor transplant, or immunotherapy, traced to leukemia evolution and exhausted T cells in the marrow.

  • Charité – Universitätsmedizin BerlinMD presenting

Special Symposium on the Basic Science of Hemostasis and Thrombosis (SSBSHT)

New tools including multiomics, protein design, functional genomics, and AI applied to how blood clots form and dissolve, and to bleeding disorders.

• Washington University in St. LouisPhD moderating
• Leiden University Medical CenterPhD moderating
• University of SydneyMBBS, PhD moderating

• Talk
  Rational Design of FVIII Variants for Gene Therapy: Linking Molecular Insight to Therapeutic Performance

  Engineering a better version of the clotting protein missing in hemophilia A for gene therapy, balancing stronger bleeding control against clot risk.

  • University of PennsylvaniaMD presenting
• Talk
  Precision in the Blood: Mapping Clotting Risk with Functional Genomics

  Using genetic association studies, multiomics, and AI to pinpoint the genes and mechanisms behind why individuals differ in their risk of blood clots.

  • Humanitas UniversityPhD presenting
• Talk
  Platelet Lipidomics and the Discovery of Novel Anti-Thrombotic Targets

  How fat molecules in platelet membranes shift during artery clotting, measured by mass spectrometry, and which could become anti-clotting drug targets.

  • University of TübingenMD presenting

Back to Business Breakfast

Networking breakfast for hematology innovators and investors, introducing a new society platform for turning blood research into companies and products.

• ModernaPhD moderating

Showcasing a Decade of Discoveries in Blood Advances

Ten years of the hematology journal Blood Advances, revisiting its most influential clinical trials, basic science studies and practice guidelines.

• Stanford UniversityMD moderating

Ancestry Origins in Personalized Medicine: Advancing Biological Discovery, Population-Representative Research Design, and Translational Validity in Hematology

How genetic ancestry shapes blood disease biology, genomic interpretation, and drug discovery, and how to build it into study design.

• Josep Carreras Leukaemia Research InstituteMD moderating
• Marian University College of Osteopathic MedicineMD moderating

• Talk
  Modeling Ancestry-Informed Bias in Hematology: Duffy-null Status and Other Genotypic Determinants

  How diverse genomic data and new computational methods improve risk prediction across populations, including ancestry effects like Duffy-null neutrophil counts.

  • Icahn School of Medicine at Mount SinaiPhD presenting
• Talk
  Leveraging our Common African Genomes to Improve Health Globally

  African genetic diversity as a driver of discovery, illustrated by sickle cell disease, kidney-risk variants, and the Duffy-null blood group.

  • Johns Hopkins UniversityMD, PhD presenting
• Talk
  African Ancestry-Associated Mechanisms of Immune System Malignancies and Precision Therapies

  African ancestry-linked differences in diffuse large B-cell lymphoma biology, such as genomic instability and immune evasion, that could reveal new drug targets.

  • Josep Carreras Leukaemia Research InstituteMD presenting

ASH Clinicians in Practice Lunch - Beyond Bandwidth: Improving Workflow Efficiency in Clinical Practice through Clinical Collaborations and Artificial Intelligence

Easing hematology clinic workload through primary care partnerships, teamwork with advanced practice providers, and AI tools that streamline workflows.

• Miami Cancer InstituteMD moderating

• Talk
  Partnering with Primary Care to Eliminate Inefficiencies

  • Oregon Health & Science UniversityMD presenting
• Talk
  AI: Artificial Intelligence as a Tool to Streamline Practice Workflows

  • Thomas Jefferson UniversityMD presenting
• Talk
  Development of Clinical Collaborations with Advanced Practice Providers to Create Efficiencies

  • Baptist Health Medical GroupMD, MPH presenting

Clinical Practice Guideline on the Treatment of Iron Deficiency with or without Anemia

New evidence-based guidance on oral versus intravenous iron for iron deficiency, with or without anemia, in children, pregnancy, and chronic blood loss.

• Baylor College of MedicineMD moderating

• Talk
  Menstruating and Pregnant Populations with Iron Deficiency and Iron Deficiency Anemia: Outcomes of Oral Versus Intravenous Iron Therapy

  • University of Alabama at BirminghamMD presenting
• Talk
  Severe Anemia, Chronic Blood Loss, or Inflammation, Oh My! Recommendations For the Treatment of Adults with Iron Deficiency

  • Oregon Health & Science UniversityMD presenting
• Talk
  Indications and Approach to Iron Replacement Therapies in Children with Iron Deficiency

  • Nationwide Children's HospitalMD, MSc presenting

Clinical Practice Guideline on the Treatment of Light-Chain Amyloidosis

Guideline advice for light-chain amyloidosis on first-line therapy, stem cell transplant, response-adapted treatment, and relapsed disease.

• Princess Margaret Cancer CentreMD moderating

• Talk
  How Deep Is Deep Enough? Response-Guided ASCT Decisions in AL Amyloidosis

  • Atrium Health Levine Cancer InstituteMD presenting
• Talk
  Front-Line Therapy for Transplant-Eligible AL Amyloidosis

  • Boston Medical CenterMD presenting
• Talk
  Relapsed and Refractory AL Amyloidosis

  • UW Carbone Cancer CenterMD presenting

Early Faculty Career Development Session

Surviving early academic careers in hematology, from non-academic career paths and diversified funding to imposter syndrome, saying no, and negotiating.

• UPMC Hillman Cancer CenterMD moderating

• Talk
  Tackling Common Obstacles - Panelist 3

  • Mayo ClinicMD presenting
• Talk
  How to Pursue Non-Traditional Academic Careers - Part 1

  • Mass General Brigham Cancer InstituteMD, MSc presenting
• Talk
  Diversifying Funding - Part 1

  • National Heart, Lung, and Blood InstituteMD presenting
• Talk
  How to Pursue Non-Traditional Academic Careers - Part 2

  • AstraZenecaMD presenting
• Talk
  Tackling Common Obstacles - Panelist 4

  • Novo NordiskMD presenting
• Talk
  Tackling Common Obstacles - Panelist 1

  • Stanford Cancer CenterMD presenting
• Talk
  Tackling Common Obstacles - Panelist 2

  • University of Wisconsin–MadisonMD, MS presenting
• Talk
  Diversifying Funding - Part 2

  • Van Andel InstituteMD presenting

Fireside Chats on Innovation in a Changing Regulatory Landscape

How FDA priorities, investor reactions to regulatory uncertainty, and new modeling tools shape the development of hematology discoveries into therapies.

• ModernaPhD moderating

• Talk
  Regulatory Environment

  • UCLAMD, PhD presenting
• Talk
  NAMs in the New Regulatory Landscape

  • Emory UniversityMD, PhD presenting
• Talk
  Closing Remarks

  • ModernaPhD presenting
• Talk
  Opening Remarks

  • ModernaPhD presenting
• Talk
  Investor Perspective: The Changing Regulatory Landscape

  • NYBC VenturesMPH presenting

From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice

Case studies showing how real-world multiple myeloma data reveal treatment patterns, outcomes in underrepresented groups, and care gaps, along with their limits.

• Memorial Sloan Kettering Cancer CenterMD moderating

• Talk
  Panel Discussion, Audience Q&A, and Closing Remarks

  • Memorial Sloan Kettering Cancer CenterMD presenting
• Talk
  Welcome and Opening Remarks

  • Memorial Sloan Kettering Cancer CenterMD presenting
• Talk
  ASH Research Collaborative Multiple Myeloma Research Network: Building Actionable Evidence at Scale

  • Mayo ClinicMD presenting
• Talk
  International Myeloma Working Group (IMWG) Perspective: From Multinational Real-World Data to Global Myeloma Guidelines

  • Mayo ClinicMD, PhD presenting
• Talk
  United States Experience: Real-World Evidence from U.S. Practice: Treatment Patterns, Outcomes, and Quality Improvement

  • Moffitt Cancer CenterMD presenting
• Talk
  Europe/Asia Perspective: Real-World Evidence from Diverse Health Care Systems: Treatment Patterns, Outcomes, and Quality Improvement (Part 2)

  • National University of SingaporeMD, PhD, MBBS presenting
• Talk
  Europe/Asia Perspective: Real-World Evidence from Diverse Health Care Systems: Treatment Patterns, Outcomes, and Quality Improvement (Part 1)

  • University of HelsinkiMD, PhD presenting

Medical Educators' Symposium

Practical strategies for medical educators on time management, wellness, inclusive learning spaces, and teaching with AI, apps, and social media.

• Moffitt Cancer CenterMD moderating

• Talk
  Breakout 2: Fostering Critical Thinking and a Feedback Culture

  • Johns Hopkins UniversityMD, MHS presenting
• Talk
  Breakout 1: Best AI and Social Media Tools to Support Instruction

  • Rutgers Cancer InstituteMD presenting
• Talk
  General Session 2: Educator Wellness

  • University of North Carolina at Chapel HillMD presenting
• Talk
  Breakout 3: Time Management for Educators

  • Duke UniversityMD, MS presenting
• Talk
  General Session 3: MEI project presentation

  • Brown UniversityMD presenting
• Talk
  Break 4: Creating Engaging Environments for Learners

  • Children's Hospital Los AngelesMD, MPH presenting
• Talk
  General Session 1: How to Use AI for Curriculum Development

  • MLL Munich Leukemia LaboratoryMD, PhD presenting

QI Intensive - A Practical Guide to Quality Improvement in Hematology

Quality improvement methods for hematology practice, from spotting care gaps and writing aim statements to choosing measures that show real change.

• University of VirginiaMD moderating

• Talk
  Process Analysis Tools and Introduction to Data in Quality Improvement

  • University of VirginiaMD presenting
• Talk
  Understanding the Problem and Developing Measures within Quality Improvement

  • McMaster UniversityMSc, MD, FRCPC presenting

Real-World Data Applications in Sickle Cell Disease Trial Design

Using sickle cell disease registries and health records to build external control arms, track safety after approval, and define pain as a trial endpoint.

• Penn MedicineMD moderating

• Talk
  Real World Registry Controls Versus Synthetic Data: Safeguarding Validity in Trial Design

  • Stanford UniversityPhD, MPH, MS presenting
• Talk
  EHR to Evidence: Defining Acute Sickle Cell Pain as a Real-World Data Endpoint

  • Duke UniversityPhD presenting
• Talk
  Panel Discussion and Q&A

  • Penn MedicineMD presenting
• Talk
  Welcome and Opening Remarks

  • Penn MedicineMD presenting
• Talk
  Using the SCD Data Hub as a Contemporaneous Control Arm in a Clinical Trial

  • Agios PharmaceuticalsMD presenting
• Talk
  Simulating Placebo Control Arms Using Real-World Registry Data in Sickle Cell Disease Trials

  • PfizerMD, PhD presenting

The AI Colleague: Promise, Peril, and Practice in Hematology

Generative AI in hematology, from chatbot tools usable today to autonomous agents, and safeguards for reliability, bias, and human oversight.

• Memorial Sloan Kettering Cancer CenterMD, PhD moderating

• Talk
  Limitations and Risks of Generative AI

  Where generative AI fails in medicine, from hallucinations and bias to rare-disease blind spots, and how validation, governance, and human oversight reduce harm.

  • Stanford UniversityMD presenting
• Talk
  Practical Generative AI Tools for Clinicians and Investigators

  Using generative AI in hematology clinics and labs, from prompt writing to literature review, coding and data analysis, while protecting data privacy.

  • Ohio State University Comprehensive Cancer CenterMD presenting
• Talk
  Multi-Agent AI systems

  AI agents that reason, plan, use tools, and work together on complex scientific and clinical tasks, and how they may change the hematologist's role.

  • TUD Dresden University of TechnologyMD presenting

The Future of Clinical Endpoints in Sickle Cell Disease

Better sickle cell disease trial endpoints than pain-crisis counts, such as biomarkers, combined measures, and patient-reported outcomes reflecting daily burden.

• Children's Hospital of PhiladelphiaMD MPH moderating

• Talk
  Welcome and Opening Remarks

  • Children's Hospital of PhiladelphiaMD MPH presenting
• Talk
  Advancing SCD Endpoints: Multidisciplinary Perspectives - Panel Discussion - Moderator

  • University of MichiganPhD presenting
• Talk
  Advancing SCD Endpoints: Multidisciplinary Perspectives - Panel Discussion - Panelist 2

  • National Heart, Lung, and Blood InstituteMD presenting
• Talk
  Advancing SCD Endpoints: Multidisciplinary Perspectives - Panel Discussion - Panelist 5

  • New York Blood CenterPhD presenting
• Talk
  Setting the Stage: Progress and/or Current Landscape of SCD Endpoints

  • New York Blood CenterPhD presenting
• Talk
  Advancing SCD Endpoints: Multidisciplinary Perspectives - Panel Discussion - Panelist 3

  • Biotechnology Innovation Organization1 speaker presenting
• Talk
  Advancing SCD Endpoints: Multidisciplinary Perspectives - Panel Discussion - Panelist 4

  • Northern Illinois UniversityPhD presenting

The Predicament of Patients in Prison: A Hematology Perspective

• VersitiMD, PhD moderating

• Talk
  Subject Matter Expert

  • UCSF1 speaker presenting
  • Tulane University School of Medicine1 speaker presenting
• Talk
  Lived Experience Expert Representative

  • Formerly Incarcerated Transitions (FIT) Clinic1 speaker presenting
• Talk
  Hematologists

  • Vanderbilt University School of MedicineMD, MPH presenting

Training Program Directors Workshop

Supporting trainees' careers and research funding in a tough political climate, AI guidelines for fellows, and how applicants signal interest in programs.

• Vanderbilt University Medical CenterMD moderating

• Talk
  Artificial Intelligence for Program Directors (Part 2)

  • Memorial Sloan Kettering Cancer CenterMD, PhD presenting
• Talk
  Artificial Intelligence for Program Directors (Part 1)

  • Ohio State University Comprehensive Cancer CenterMD presenting
• Talk
  Supporting Fellows in their Pursuit of Research Funding and Career Placement (Part 1)

  • UCSFMD presenting
• Talk
  Insights and Experiences After One Year of Program Signaling (Part 2)

  • University of ChicagoMD presenting
• Talk
  Supporting Fellows in their Pursuit of Research Funding and Career Placement (Part 2)

  • NovartisMD, MSc presenting
• Talk
  Insights and Experiences After One Year of Program Signaling (Part 1)

  • Emplify Health by GundersenMD presenting

Treating Fairly Rounds Lunch

How hematologists and fellows can influence healthcare reform on research funding, Medicaid, and hospital budgets, and how policy shapes health inequities.

• Mayo ClinicMD, MPH moderating
• Ohio State University Comprehensive Cancer CenterMD moderating

• Talk
  Challenges and Opportunities with Healthcare Reform (Perspective 2)

  • Dana-Farber Cancer InstituteMD, MPH presenting
• Talk
  Challenges and Opportunities with Healthcare Reform (Perspective 1)

  • University of Oklahoma Health Sciences CenterPhD presenting

Women in Hematology Networking Dinner Event

Negotiation strategies for women in hematology, covering how to negotiate for roles and future opportunities and build lasting advocacy networks.

• Atrium Health Levine Cancer InstituteMD moderating

• Talk
  Difficult Conversations: Respect Under Tension

  • Duke UniversityMD, MS presenting
• Talk
  Influence: Voice, Credibility, and Impact

  • Centre for Blood Research, University of YorkMBBS PhD presenting